// App-Quantinova.ai

TCT-315 : White Blood Cell Count and 4-Year Clinical Outcomes After Left Main Coronary Artery Revascularization: Insights From the EXCEL Trial

Researchers

Presenter

  • Bimmer Claessen

Principal Investigators

  • Ori Ben-Yehuda

  • Roxana Mehran

  • Ovidiu Dressler

  • Shmuel Chen

  • Samer Mansour

  • Nicolas Noiseux

  • A. Pieter Kappetein

  • Joseph Sabik

  • Samin Sharma

  • Annapoorna Kini

  • Patrick Serruys

  • Gregg Stone

Medical Centers

  • Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada

  • Cardiovascular Research Foundation, Columbia University Medical Center, New York, New York

  • Imperial College, London, United Kingdom

  • Cardiovascular Research Foundation, New York, New York, USA

  • Medtronic, Mounds View, Minnesota

  • Mount Sinai Health System, New York, New York

  • Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, Ohio

  • The Zena and Michael A. Wiener Cardiovascular Institute, Mount Sinai Hospital, New York, NY

Locations

  • Canada

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Left main disease

Biomarkers

  • Lymphocyte count

  • White Blood Cell

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved